3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Pseudomyxoma Peritonei
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Kidney Transplantation
1
Interventions
Cyclophosphamide
48
fludarabine
32
Methotrexate
24
blinatumomab
20
fludarabine phosphate
19
Dexamethasone
19
Vincristine
18
Whole-Body Irradiation
16
Specimen Handling
16
Cytarabine
16
Tacrolimus
14
Mycophenolic Acid
14
Peripheral Blood Stem Cell Transplantation
13
Melphalan
13
Mercaptopurine
12
Calcium Dobesilate
12
merphos
11
Busulfan
11
Biopsy
11
Magnetic Resonance Spectroscopy
10
Etoposide
10
Stem Cell Transplantation
9
Prednisone
9
Granulocyte Colony-Stimulating Factor
9
Cyclosporine
9
Thiotepa
8
Rituximab
8
Mesna
8
Filgrastim
8
Doxorubicin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Alemtuzumab
×
90 days
×
Clear all
NCT03821610
2026-05-05
ALL-RIC
University of Birmingham
Phase 2
Active not recruiting
242 enrolled